A federal judge in California has dismissed the First Amended Complaint, with leave to amend, against Acelyrin (SLRN) and several of its executives, but allowed investors another opportunity to revise and refile their claims. The ruling addresses allegations tied to Acelyrin’s disclosures about clinical trial results for its drug candidate, izokibep.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
While the court did not reach any conclusions about liability, the decision outlines key deficiencies in the plaintiffs’ pleading and sets a tight schedule for what happens next in the case. Stay informed on major investor lawsuits and legal developments by following our updates.
Court Grants Motion to Dismiss With Leave to Amend
On January 26, 2026, the U.S. District Court for the Central District of California granted defendants’ motion to dismiss the plaintiffs’ First Amended Complaint. The court dismissed all claims with leave to amend, meaning the case is not over and plaintiffs may attempt to fix the identified problems by filing a new complaint.
The lawsuit was brought on behalf of investors who purchased Acelyrin securities, alleging violations of federal securities laws in connection with statements and omissions about clinical trials for izokibep, a drug candidate under development.
Scienter Allegations Found Insufficient
A central issue in the ruling was whether investors adequately pleaded scienter, a required element for claims under Section 10(b) of the Securities Exchange Act and Rule 10b-5. Scienter refers to an intent to deceive or deliberate recklessness.
The court expressed skepticism that the complaint plausibly alleged scienter. According to the order, plaintiffs relied on two main theories: that defendants knew or were reckless in omitting information about patient discontinuation rates in clinical trials, and that defendants were motivated to conceal this information to support Acelyrin’s initial public offering and stock price.
The judge found that this theory did not convincingly explain why defendants would conceal information if disappointing trial results were expected to emerge later anyway. The court also noted the absence of allegations that insiders sold stock while prices were allegedly inflated, undermining claims of a financial motive.
Questions About Materiality of Alleged Omissions
The court also questioned whether the alleged omissions were material, meaning whether a reasonable investor would view the information as significantly altering the total mix of available information.
Plaintiffs alleged defendants omitted discontinuation rates and omitted/failed to disclose key details about the statistical methodologies used for Part A and Part B. The court was not persuaded that investors would necessarily have viewed this information as materially changing their investment decisions, particularly given uncertainty about what the alternative results would have shown.
Safe Harbor and Securities Act Claims
Not all of defendants’ arguments were accepted. The Court expressed skepticism toward defendants’ argument that the PSLRA’s safe harbor for forward-looking statements barred plaintiffs’ claims, explaining that the statute does not categorically shield mixed statements that combine forward-looking projections with alleged misstatements or omissions of present fact.
However, the court agreed that plaintiffs’ claims under Sections 11 and 15 of the Securities Act of 1933 appeared to sound in fraud and therefore were subject to heightened pleading standards.
What Happens Next in the Acelyrin Case
The court ordered plaintiffs to file a Second Amended Complaint or a notice stating they intend to stand on the dismissed complaint by February 5, 2026. If plaintiffs fail to act, the case may be dismissed for failure to prosecute.
The court also directed plaintiffs to clarify whether the estate of a deceased co-lead plaintiff intends to continue participating in the case. Defendants must respond to any new complaint by February 19, 2026, and the court outlined procedures for any renewed motion to dismiss.
For more court rulings and updates on securities lawsuits, follow us.
Why This Ruling Matters to Investors
This decision highlights the high pleading standards investors must meet in securities fraud cases, particularly when claims are based on complex scientific and clinical trial disclosures. The court emphasized that allegations of motive and omission must be supported by detailed, compelling facts—not just general assertions about stock prices or business incentives.
Importantly, the dismissal does not resolve whether Acelyrin or its executives committed any wrongdoing. The court made clear that its analysis was procedural and did not constitute a determination of liability.
About Levi & Korsinsky, LLP
Levi & Korsinsky, LLP is a nationally recognized securities litigation firm representing investors in complex shareholder actions. The firm has recovered hundreds of millions of dollars for investors and is consistently ranked among the leading U.S. securities class action firms. Attorney advertising. Prior results do not guarantee similar outcomes.
Legal Disclaimer: This article is provided for informational purposes only and does not constitute legal advice. No attorney-client relationship is created by reading this article.